Kristie L. Kahl

Articles

Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC

May 20, 2020

Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.

FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC

January 16, 2020

The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.